The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2019 Cell & Gene Meeting on the Mesa

WASHINGTON, DC – July 24, 2019

The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, today released the initial slate of presenting companies at the 2019 Cell & Gene Meeting on the Mesa. The event will be held October 2-4 in Carlsbad, California, with company presentations taking place throughout all three days.

This year’s event is expected to attract more than 1,200 attendees, including senior executives from leading cell therapy, gene therapy, and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research institutions, patient foundations and disease philanthropies, life science media, and more.

The Cell & Gene Meeting on the Mesa features presentations by 75+ leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.

The initial slate of 2019 presenting companies includes: 4D Molecular Therapeutics, Adaptimmune, AGTC, AIVITA Biomedical, Amicus Therapeutics, Astellas Institute for Regenerative Medicine, Atara Biotherapeutics, Athersys, Autolus, Avectas, AVROBIO, Axovant Gene Therapies, BioLife Solutions, BioTime, bluebird bio, BlueRock Therapeutics, Caladrius Biosciences, Caribou Biosciences, CARISMA Therapeutics, Casebia Therapeutics, CCRM, Cellect Biotechnology, Cells for Cells, Celsense, Covance, Cynata Therapeutics, DiscGenics, Fate Therapeutics, Fibrocell Science, Flexion Therapeutics, FUJIFILM Cellular Dynamics, Gamida Cell, Genprex, Giner Life Sciences, Gyroscope Therapeutics, HEALIOS K.K., Homology Medicines, Iovance Biotherapeutics, IVERIC bio, Krystal Biotech, Kytopen, LogicBio , Magenta Therapeutics, MaxCyte, Medeor Therapeutics, Miromatrix Medical, MolMed S.p.A., Novadip Biosciences, Opsis Therapeutics, Orchard Therapeutics, Organovo, Oxford Biomedica, PDC*line Pharma, PolarityTE, Poseida Therapeutics, Precision BioSciences, Regenerative Patch Technologies, REGENXBIO, ReNeuron, Sangamo Therapeutics, SCM Lifescience, Senti Biosciences, Sentien Biotechnologies, Sigilon Therapeutics, StemBioSys, Synpromics, Talaris Therapeutics, Terumo BCT, Tmunity Therapeutics, uniQure, VERIGRAFT, ViaCyte, Vivet Therapeutics, WindMIL Therapeutics, and Zelluna Immunotherapy.

Additional event details will be updated regularly on the conference website –

Registration is complimentary for investors and credentialed members of the media. To learn more and to register, please visit For members of the media interested in attending, please contact Lyndsey Scull at

For interested organizations looking to increase exposure to this field’s top decision-makers via sponsorship, please contact Laura Parsons at for additional information.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit

# # #